TY - JOUR
T1 - Local release of fibrinolytic agents for adhesion prevention
AU - Hill-West, Jennifer L.
AU - Dunn, Randall C.
AU - Hubbell, Jeffrey A.
PY - 1995/12
Y1 - 1995/12
N2 - Tissue plasminogen activator (tPA), urokinase plasminogen activator (uPA), and streptokinase were evaluated for their ability to reduce postsurgical adhesion formation in a rat uterine horn devascularization and serosal injury model in a blinded, randomized study. Small doses of tPA, uPA, or streptokinase were delivered over approximately a 4-day period either from a biodegradable hydrogel matrix or as four daily intraperitoneal injections. The hydrogel was formed upon the uterine horns by photopolymerization of an aqueous precursor solution containing dissolved drug. A control group that received no treatment had an average extent of adhesion formation of 72 ± 15% (mean ± SEM, percentage of the length of the uterine horns involved in adhesions). Application of this formulation of the hydrogel alone reduced the extent of adhesion formation to 22 ± 10% by functioning as a mechanical barrier. When tPA was released from the hydrogel, adhesion formation was reduced to 4 ± 3%, while when tPA was given by intraperitoneal injection, adhesion formation was only reduced to 49 ± 8%. Local delivery of urokinase reduced adhesion formation to 6 ± 6%, but intraperitoneal injection of urokinase did not reduce adhesion formation. Streptokinase did not reduce adhesion formation when administered by intraperitoneal injection and increased adhesion formation to 45 ± 9% when locally released relative to the hydrogel alone. These results suggest that both tPA and uPA may be used to prevent adhesion formation when delivered locally.
AB - Tissue plasminogen activator (tPA), urokinase plasminogen activator (uPA), and streptokinase were evaluated for their ability to reduce postsurgical adhesion formation in a rat uterine horn devascularization and serosal injury model in a blinded, randomized study. Small doses of tPA, uPA, or streptokinase were delivered over approximately a 4-day period either from a biodegradable hydrogel matrix or as four daily intraperitoneal injections. The hydrogel was formed upon the uterine horns by photopolymerization of an aqueous precursor solution containing dissolved drug. A control group that received no treatment had an average extent of adhesion formation of 72 ± 15% (mean ± SEM, percentage of the length of the uterine horns involved in adhesions). Application of this formulation of the hydrogel alone reduced the extent of adhesion formation to 22 ± 10% by functioning as a mechanical barrier. When tPA was released from the hydrogel, adhesion formation was reduced to 4 ± 3%, while when tPA was given by intraperitoneal injection, adhesion formation was only reduced to 49 ± 8%. Local delivery of urokinase reduced adhesion formation to 6 ± 6%, but intraperitoneal injection of urokinase did not reduce adhesion formation. Streptokinase did not reduce adhesion formation when administered by intraperitoneal injection and increased adhesion formation to 45 ± 9% when locally released relative to the hydrogel alone. These results suggest that both tPA and uPA may be used to prevent adhesion formation when delivered locally.
UR - http://www.scopus.com/inward/record.url?scp=0029608717&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0029608717&partnerID=8YFLogxK
U2 - 10.1006/jsre.1995.1236
DO - 10.1006/jsre.1995.1236
M3 - Article
C2 - 8538178
AN - SCOPUS:0029608717
SN - 0022-4804
VL - 59
SP - 759
EP - 763
JO - Journal of Surgical Research
JF - Journal of Surgical Research
IS - 6
ER -